Drug Profile
Research programme: diagnostic and therapeutic products - Dyax/EPIX Pharmaceuticals
Latest Information Update: 27 Mar 2008
Price :
$50
*
At a glance
- Originator Dyax; EPIX Pharmaceuticals
- Class Imaging agents; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 23 Nov 2004 Preclinical trials in Thrombosis in USA (unspecified route)